With implementation due on 28 April 2026, the MHRA’s ICH GCP E6(R3) rollout is turning GCP compliance into an immediate operational issue for UK sponsors
Drug discovery timelines are still measured in years—despite billions invested in AI.
So which platforms are genuinely accelerating R&D—and which are just adding another layer of complexity?
We analysed BenevolentAI, Atomwise, and Insilico Medicine to find out.
I’ve spent 20+ years validating static systems.
Now I’m watching real-time analytics platforms make decisions faster than we can explain, justify, or defend them.
That should make every GxP leader pause
AI in pharma just crossed a quiet line.
Not in production. Not in pilots.
But inside regulatory sandboxes designed to test what should be allowed next.
One robot arm. One sterile isolator. Zero human intervention.
The twist? The AI deciding what happens in Grade A hasn’t actually been approved—or deployed—yet.
90% of pharma AI pilots never scale. I’ve seen the pattern—and it’s not data or models. It’s the absence of explainable AI when regulators start asking questions.
